Cargando…

The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review

Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are urgently needed. The bright expression of the C...

Descripción completa

Detalles Bibliográficos
Autores principales: Prejzner, Witold, Piekoś, Oliwia, Bełdzińska, Karolina, Sadowska-Klasa, Alicja, Zarzycka, Ewa, Bieniaszewska, Maria, Lewandowski, Krzysztof, Zaucha, Jan Maciej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628456/
https://www.ncbi.nlm.nih.gov/pubmed/37941558
http://dx.doi.org/10.3389/fonc.2023.1228481
_version_ 1785131762765004800
author Prejzner, Witold
Piekoś, Oliwia
Bełdzińska, Karolina
Sadowska-Klasa, Alicja
Zarzycka, Ewa
Bieniaszewska, Maria
Lewandowski, Krzysztof
Zaucha, Jan Maciej
author_facet Prejzner, Witold
Piekoś, Oliwia
Bełdzińska, Karolina
Sadowska-Klasa, Alicja
Zarzycka, Ewa
Bieniaszewska, Maria
Lewandowski, Krzysztof
Zaucha, Jan Maciej
author_sort Prejzner, Witold
collection PubMed
description Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are urgently needed. The bright expression of the CD38 antigen found in several cases of T-ALL led to an investigation into the role of anti-CD38 antibodies in the treatment of T-ALL. Here, we present three cases of resistant and relapsed T-ALL and myeloid/T-cell treated with daratumumab-based therapy, including venetoclax and bortezomib (Dara-Ven-Bor). All patients achieved complete remission, with minimal residual disease negativity within four weeks of treatment, allowing them to proceed to allogeneic hematopoietic cell transplantation. The toxicity of the triple schema was acceptable. Our patients and other cases reviewed here suggest that daratumumab combined with venetoclax and bortezomib may be a very effective and relatively safe salvage treatment, even in primary resistant T-ALL.
format Online
Article
Text
id pubmed-10628456
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106284562023-11-08 The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review Prejzner, Witold Piekoś, Oliwia Bełdzińska, Karolina Sadowska-Klasa, Alicja Zarzycka, Ewa Bieniaszewska, Maria Lewandowski, Krzysztof Zaucha, Jan Maciej Front Oncol Oncology Primary refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL) and mixed phenotype myeloid/T-cell acute leukemia have dismal prognoses. New treatment approaches, preferably targeting specific leukemic aberrations to overcome resistance, are urgently needed. The bright expression of the CD38 antigen found in several cases of T-ALL led to an investigation into the role of anti-CD38 antibodies in the treatment of T-ALL. Here, we present three cases of resistant and relapsed T-ALL and myeloid/T-cell treated with daratumumab-based therapy, including venetoclax and bortezomib (Dara-Ven-Bor). All patients achieved complete remission, with minimal residual disease negativity within four weeks of treatment, allowing them to proceed to allogeneic hematopoietic cell transplantation. The toxicity of the triple schema was acceptable. Our patients and other cases reviewed here suggest that daratumumab combined with venetoclax and bortezomib may be a very effective and relatively safe salvage treatment, even in primary resistant T-ALL. Frontiers Media S.A. 2023-10-24 /pmc/articles/PMC10628456/ /pubmed/37941558 http://dx.doi.org/10.3389/fonc.2023.1228481 Text en Copyright © 2023 Prejzner, Piekoś, Bełdzińska, Sadowska-Klasa, Zarzycka, Bieniaszewska, Lewandowski and Zaucha https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Prejzner, Witold
Piekoś, Oliwia
Bełdzińska, Karolina
Sadowska-Klasa, Alicja
Zarzycka, Ewa
Bieniaszewska, Maria
Lewandowski, Krzysztof
Zaucha, Jan Maciej
The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
title The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
title_full The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
title_fullStr The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
title_full_unstemmed The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
title_short The role of daratumumab in relapsed/refractory CD38 positive acute leukemias—case report on three cases with a literature review
title_sort role of daratumumab in relapsed/refractory cd38 positive acute leukemias—case report on three cases with a literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628456/
https://www.ncbi.nlm.nih.gov/pubmed/37941558
http://dx.doi.org/10.3389/fonc.2023.1228481
work_keys_str_mv AT prejznerwitold theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT piekosoliwia theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT bełdzinskakarolina theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT sadowskaklasaalicja theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT zarzyckaewa theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT bieniaszewskamaria theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT lewandowskikrzysztof theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT zauchajanmaciej theroleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT prejznerwitold roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT piekosoliwia roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT bełdzinskakarolina roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT sadowskaklasaalicja roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT zarzyckaewa roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT bieniaszewskamaria roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT lewandowskikrzysztof roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview
AT zauchajanmaciej roleofdaratumumabinrelapsedrefractorycd38positiveacuteleukemiascasereportonthreecaseswithaliteraturereview